According to the related industry, Servier Korea's Oncaspar (Pegaspargase) was approved from the MFDS as a rare specialty medicine as a combination therapy with other anti-tumor drugs when treating Acute Lymphoblastic Leukemia (ALL) in children and adults under the age of 8 years.

Oncaspar is a drug that dramatically reduces the frequency of administration so that it is administered once every 14 days compared to L-asparaginase, which was previously administered once every other day by maximizing the drug circulation half-life through PEGylation.

Considering the high incidence rate of acute lymphocytic leukemia, especially in pediatric patients, it is expected to alleviate the physical pa